Emergence of a STAT3 mutated NK clone in LGL leukemia
Publication date: Available online 16 December 2014 Source:Leukemia Research Reports Author(s): Yiyi Yan , Thomas L. Olson , Susan B. Nyland , David J. Feith , Thomas P. Loughran Jr. Large granular lymphocyte (LGL) leukemia is a chronic clonal lymphoproliferative disorder. A patient with T-LGL leukemia was followed for 12 years; later, he developed NK-LGL leukemia with residual leukemic T-LGL. Dynamic TCRVβ usage and CDR3 sequence drifts correlating with disease progression were observed. A STAT3 S614R mutation was identified in NK cells in the NK/T-LGL mixed leukemic stage but not at earlier points. STAT3 activa...
Source: Leukemia Research Reports - January 9, 2015 Category: Hematology Source Type: research
“Preleukemic or Smoldering” chronic Myelogenous leukemia (CML):BCR-ABL1 positive: A brief case report
We report a case of confirmed Ph+CML with a normal CBC detected because of the presence of rare myelocytes and 2% basophils. [Fig. 1] Previous leukocyte counts for the preceding 8 years were normal with the exception of one done 4 months prior to his presentation that showed an abnormal differential with 1% basophils, 2% metamyelocytes and 2% myelocytes. (Source: Leukemia Research Reports)
Source: Leukemia Research Reports - January 9, 2015 Category: Hematology Source Type: research
Acute promyelocytic leukemia with JAK2 V617F and severe differentiation syndrome
We report a case of essential thrombocythemia that transformed into acute promyelocytic leukemia (APL) with both the t(15;17) translocation as well as the JAK2 V617F mutation. Clinically, this case was notable for severe differentiation syndrome despite treatment with high-dose dexamethasone. Cytokine production by differentiating APL cells was not directly abrogated by JAK2 inhibitors in vitro, suggesting that JAK2 V617F enhances the hyperinflammatory response downstream of cytokines. JAK1/2 inhibitors may therefore dampen the inflammatory cascade downstream of cytokine production, similar to glucocorticoids, and have a r...
Source: Leukemia Research Reports - January 9, 2015 Category: Hematology Source Type: research
Progressive transfusion and growth factor independence with adjuvant sertraline in low risk myelodysplastic syndrome treated with an erythropoiesis stimulating agent and granulocyte-colony stimulating factor
Publication date: 2015 Source:Leukemia Research Reports, Volume 4, Issue 1 Author(s): Kirtan Nautiyal , Rui Li , Sarvari Yellapragada , Perumal Thiagarajan , Martha Mims , Gustavo Rivero Refractoriness to growth factor therapy is commonly associated with inferior outcome in patients with low-risk myelodysplastic syndrome (LR-MDS) who require treatment for cytopenias. However, the mechanisms leading to refractoriness are unknown. Here we describe a clinically depressed 74-year-old male with refractory cytopenia with multilineage dysplasia (RCMD) and documented growth factor refractory anemia after erythropoeisis s...
Source: Leukemia Research Reports - January 9, 2015 Category: Hematology Source Type: research
Reviewer List
Publication date: 2014 Source:Leukemia Research Reports, Volume 3, Issue 2 (Source: Leukemia Research Reports)
Source: Leukemia Research Reports - December 4, 2014 Category: Hematology Source Type: research
A novel del(8)(q23.2q24.11) contributing to disease progression in a case of JAK2/TET2 double mutated chronic myelomonocytic leukemia
Publication date: 2014 Source:Leukemia Research Reports, Volume 3, Issue 2 Author(s): Marie Toft-Petersen , Eigil Kjeldsen , Line Nederby , Kirsten Grønbæk , Peter Hokland , Anne Stidsholt Roug We have identified a novel 7.7Mb del(8)(q23.2q24.11) in a patient progressing to acute myeloid leukemia (AML) following a 12-year stable phase of chronic myelomonocytic leukemia (CMML). A surprisingly high JAK2+ allelic burden of 92% at the time of AML led us to delineate the molecular aberrations relevant for leukemogenesis. While a frameshift mutation in the TET2 gene was stably present throughout the course of disease...
Source: Leukemia Research Reports - December 4, 2014 Category: Hematology Source Type: research
Successful HLA haploidentical myeloablative stem cell transplantation for aggressive hepatosplenic alpha/beta (αβ) T-cell lymphoma
Publication date: 2014 Source:Leukemia Research Reports, Volume 3, Issue 2 Author(s): Gioacchino Catania , Francesco Zallio , Federico Monaco , Maria Teresa Corsetti , Nicol Trincheri , Lisa Bonello , Lia Mele , Franco Dallavalle , Flavia Salvi , Massimo Pini Hepatosplenic T cell lymphoma (HSTCL) is a type of hematologic neoplasia with a poor prognosis and a high frequency of refractoriness to conventional chemotherapy. The results obtained by high dose chemotherapy followed by autologous stem cells transplantation seem to be a more effective option but still unsatisfactory. Also the role of allogeneic stem c...
Source: Leukemia Research Reports - December 4, 2014 Category: Hematology Source Type: research
Deletion and deletion/insertion mutations in the juxtamembrane domain of the FLT3 gene in adult acute myeloid leukemia
We report two cases of AML with uncommon in-frame mutations in the juxtamembrane domain of the FLT3 gene: a 3-bp (c.1770_1774delCTACGinsGT; p.F590_V592delinsLF) deletion/insertion and a 12-bp (c.1780_1791delTTCAGAGAATAT; p.F594_Y597del) deletion. We verified by sequencing that the reading frame of the FLT3 gene was preserved and by cDNA analysis that the mRNA of the mutant allele was expressed in both cases. Given the recent development of FLT3 inhibitors, our findings may be of therapeutic value for AML patients harboring similar FLT3 mutations. (Source: Leukemia Research Reports)
Source: Leukemia Research Reports - December 4, 2014 Category: Hematology Source Type: research
The use of low-dose protracted oral clofarabine in a patient with myelodysplastic syndrome after failing 5-azacitidine
We report our experience with low-dose protracted oral clofarabine in one patient who achieved stable disease for more than two years after failing 5-azacitidine. (Source: Leukemia Research Reports)
Source: Leukemia Research Reports - October 12, 2014 Category: Hematology Source Type: research
Large granular lymphocytic leukemia associated with Lambert–Eaton Myasthenic Syndrome: A case report
Publication date: 2013 Source:Leukemia Research Reports, Volume 2, Issue 1 Author(s): Richard Lemal , Carine Chaleteix , Patrice Minard , Corinne Roche , Jacques-Olivier Bay , Olivier Tournilhac , Thierry Lamy Large granular lymphocytic (LGL) leukemia is an uncommon clonal lymphoproliferative disorder. Lambert–Eaton Myasthenic Syndrome (LEMS) is a rare neuromuscular autoimmune disease caused by pathogenic autoantibodies targeting the voltage-gated calcium channels (VGCC) on the presynaptic nerve terminal. We here describe the case of a 77-year old patient with LGL leukemia, associated with a seropositive and s...
Source: Leukemia Research Reports - October 12, 2014 Category: Hematology Source Type: research
A successful renal transplantation for renal failure after dasatinib-induced thrombotic thrombocytopenic purpura in a patient with imatinib-resistant chronic myelogenous leukaemia on nilotinib
We report the case of a CML in first chronic phase who was diagnosed in August 2003 in a young 24 year-old Caucasian woman. Our patient received first imatinib and then dasatinib and nilotinib. Imatinib was well tolerated and she developed TTP/HUS on dasatinib without documented evolution of CML and finally obtained MR5.0 with nilotinib and without any side effect. This case also illustrates the absence of cross-resistance and side-effects between the different TKIs and the feasibility of kidney transplantation associated with a nilotinib treatment of CML allowing a continuing MR5.0 and no further side effects. (Source: Le...
Source: Leukemia Research Reports - October 12, 2014 Category: Hematology Source Type: research
Evaluation of early discharge after hospital treatment of neutropenic fever in acute myeloid leukemia (AML)
Conclusions Our results suggest that an ANC of 500 is an excessively high cut off for discharge following hospitalization for neutropenic fever. The rate of rise of the ANC, as well as its absolute value, may also play a role. (Source: Leukemia Research Reports)
Source: Leukemia Research Reports - October 12, 2014 Category: Hematology Source Type: research
GATA2 zinc finger 2 mutation found in acute myeloid leukemia impairs myeloid differentiation
Publication date: 2013 Source:Leukemia Research Reports, Volume 2, Issue 1 Author(s): Keiko Niimi , Hitoshi Kiyoi , Yuichi Ishikawa , Fumihiko Hayakawa , Shingo Kurahashi , Rika Kihara , Akihiro Tomita , Tomoki Naoe We identified two novel GATA2 mutations in acute myeloid leukemia (AML). One mutation (p.R308P-GATA2) was a R308P substitution within the zinc finger (ZF)-1 domain, and the other (p.A350_N351ins8-GATA2) was an eight-amino-acid insertion between A350 and N351 residues within the ZF-2 domain. p.R308P-GATA2 did not affect DNA-binding and transcriptional activities, while p.A350_N351ins8-GATA2 reduced t...
Source: Leukemia Research Reports - October 12, 2014 Category: Hematology Source Type: research
Strategies to circumvent the T315I gatekeeper mutation in the Bcr-Abl tyrosine kinase
Publication date: 2013 Source:Leukemia Research Reports, Volume 2, Issue 1 Author(s): Prithviraj Bose , Haeseong Park , Jawad Al-Khafaji , Steven Grant Despite the remarkable success of imatinib against Bcr-Abl, development of secondary resistance, most often due to point mutations in the Bcr-Abl tyrosine kinase (TK) domain, is quite common. Of these, the T315I “gatekeeper” mutation is resistant to all currently registered Bcr-Abl TK inhibitors (TKIs) with the notable exception of ponatinib (Iclusig™), which was very recently approved by the United States Food and Drug Administration (FDA). Besides ponatinib,...
Source: Leukemia Research Reports - October 12, 2014 Category: Hematology Source Type: research
Two copies of isochromosome 5p in refractory cytopenia with multilineage dysplasia: A case report
Publication date: 2013 Source:Leukemia Research Reports, Volume 2, Issue 1 Author(s): Carolina Giudici , Riccardo Lingeri , Carlo Patriarca , Alessandra Cavallero , Michele Partenope , Floredana Casasanta , Raffaella Epifani , Monica Giordano Isochromosome 5p-i(5)(p10)-represents a rare but recurrent abnormality in myeloid disorders, especially in acute myeloid leukemia. In all published cases, the isochromosome 5p was present in single copy and accompanied by one or more additional anomalies, mostly trisomy 8. Here we report a case of refractory cytopenia with multilineage dysplasia with two copies of isochrom...
Source: Leukemia Research Reports - October 12, 2014 Category: Hematology Source Type: research
